Day: January 8, 2026

Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025 Annual Nociscan scan volumes increased 69% year-over-year in 2025 Debt-free balance sheet with $12.0 million in cash as of December 31, 2025, extending cash runway into 2027 and providing strategic flexibility for continued commercial growth Company aims to enroll approximately 25% of patients in CLARITY trial by the end of Q2 2026, with the first internal readout on interim data anticipated in Q3 2026BROOMFIELD, Colo., Jan. 08, 2026 (GLOBE NEWSWIRE) — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain today provided a comprehensive corporate...

UNITED KINGDOM, Jan. 08, 2026 (GLOBE NEWSWIRE) — Energys Group Limited (NASDAQ: ENGS) (“Energys Group” or the “Company”), a vertically integrated energy efficiency and decarbonization solutions provider for the build environment, today announced the receipt of a letter dated December 30, 2025 (the “Determination Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”). The Determination Letter indicated that the minimum market value of the Company’s listed security (the “MVLS”) was below the required MVLS of $35 million for the past 30 consecutive business days and, as a result, the Company did not comply with Listing Rule 5550(b)(2) (the “Rule”). Nasdaq calculates the Company’s MVLS based upon the most recent total shares outstanding multiplied by the closing bid price. In accordance with Listing...

BEIJING, Jan. 08, 2026 (GLOBE NEWSWIRE) — JD.com, Inc. (NASDAQ: JD and HKEX: 9618 (HKD counter) and 89618 (RMB counter), the “Company” or “JD.com”), a leading supply chain-based technology and service provider, today announced updates of its share repurchase and cancellation. The Company repurchased a total of approximately 183.2 million Class A ordinary shares (equivalent to 91.6 million American depositary shares, “ADSs”) for a total of approximately US$3.0 billion in 2025. The total number of these repurchased shares amounted to approximately 6.3% of the Company’s total ordinary shares outstanding as of December 31, 2024. All of the 183.2 million Class A ordinary shares (equivalent to 91.6 million ADSs) repurchased in 2025 have been cancelled as of the date of this announcement. These repurchases were made from both Nasdaq and...

NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) — Global Net Lease, Inc. (NYSE: GNL) (“GNL” or the “Company”) today announced the successful completion of its key strategic objectives in 2025, a year of significant transformation that strengthened the Company’s balance sheet, enhanced operational performance and strategically aligned its portfolio to support long-term growth and deliver sustained shareholder value. “2025 was a pivotal year for GNL,” said Michael Weil, CEO. “We took deliberate steps to materially improve the Company’s financial and operational profile, creating a durable platform for long-term growth. Looking ahead to 2026, we are focused on driving earnings growth through share repurchases, selective acquisitions, or a combination of both, while opportunistically divesting assets when value is compelling. We plan to continue...

Groupama announced the issue on 7 January 2026 of EUR 600 million in fixed-rate Restricted Tier1 perpetual notes, subscribed by institutional investors and offering a fixed coupon of 5.750%. The purpose of this transaction was to take advantage of current supportive market conditions to optimize the group’s capital structure. Investors showed significant interest in the new notes, with the final order book oversubscribed by more than four times. The main terms of the new issue are the following:Issuer: Groupama Assurances MutuellesRating of the notes: BBB by Fitch RatingsIssue amount: EUR 600 millionPricing date: 7 January 2026Settlement date: 14 January 2026Coupon: 5.750 per centISIN: FR0014014IQ4 J.P. Morgan (Global Coordinator), Citigroup, Crédit Agricole CIB, Morgan Stanley, Natixis and Société Générale CIB acted as joint bookrunners...

EXTREMELY RARE OPPORTUNITY TO ACQUIRE THE F1 CAR IN WHICH MICHAEL SCHUMACHER WON HIS FIRST GRAND PRIX IN BELGIUM IN 1992 | BENETTON B192-05 USED EXCLUSIVELY BY SCHUMACHER IN FIVE GRANDS PRIX DURING 1992 F1 SEASON | THE LAST RACE-WINNING F1 CAR TO USE A MANUAL GEARBOX | CAR WAS RETAINED BY BENETTON BEFORE BECOMING PART OF THE RENAULT CLASSIC COLLECTION AND HAS NEVER BEFORE BEEN OFFERED FOR PUBLIC SALE | PART OF THE BROAD ARROW GLOBAL ICONS: EUROPE ONLINE SALE OPEN FROM 23-30 JANUARY 2026Michael Schumacher’s first Formula One Grand Prix-winning 1992 Benetton B192-05 pictured before its offering in Broad Arrow’s Global Icons: Europe Online Auction, open for bidding 23-30 January 2026.Credit – Robin Möhl / Courtesy of Broad Arrow AuctionsMichael Schumacher and his teammate Martin Brundle pose with B192-05 at the Hungarian...

21Shares AG LEI: 254900UWHMJRRODS3Z64 8 January 2026 Publication of Base Prospectus The following Base Prospectus has been approved by the Financial Conduct Authority and is available for viewing: Base Prospectus dated 8 January 2026 (the “Base Prospectus”) relating to the Exchange Traded Products Programme of 21Shares AG, available for both professional and retail clients.  To view the Base Prospectus in full, please paste the following URL into the address bar of your browser: https://www.21shares.com/en-ch/ir/prospectus A copy of the Base Prospectus will be submitted to the Financial Conduct Authority’s Electronic Submission Service and may shortly be viewed on the National Storage Mechanism at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism Enquiries: Attention of Mr. Eric Baumgartner, Head of Legal EMEA. Email address:...

VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery and Variational AI, a leader in generative artificial intelligence for small-molecule design, today announced the expansion of their collaboration focused on the continued optimization of Rakovina’s kt-5000 series of ATR inhibitors. Building on their existing collaboration, the companies have signed a new agreement to focus on lead optimization of drug candidates identified by Variational AI’s Enki™ generative AI platform and selected by Rakovina for further evaluation in the kt-5000 ATR inhibitor program. Under the expanded scope of work, Variational AI will apply its generative AI platform to iteratively...

ZUG, Switzerland, Jan. 08, 2026 (GLOBE NEWSWIRE) —Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential market of $7B+ in the U.S. alone Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) expected in Q2 2026 Riad Sherif, M.D., Chief Executive Officer, will present at the J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 1.30pm PSTOculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that the transformative potential of its late-stage pipeline,...